Bayer’s Slow Build: Clinical Evidence and Margin Pressures Define the Next Chapter
Bayer is attempting to write a new chapter, one built on clinical proof rather than corporate promises. The German conglomerate's...
Bayer is attempting to write a new chapter, one built on clinical proof rather than corporate promises. The German conglomerate's...
Despite posting a record quarterly revenue of $43.84 billion, Dell Technologies saw its stock fall 7.47 percent to €319.00 in...
NOVONIX is overhauling its C-suite as it races to transform from a development-stage company into a large-scale producer of synthetic...
IREN is no longer just a Bitcoin miner. The company is layering two massive agreements — one with Dell for...
The narrative around Realty Income has long been built on a single, near‑flawless promise: buy properties, collect rent, and pay...
The world’s largest European-listed ETF is navigating a period of rare dual tension. The iShares Core MSCI World UCITS ETF...
ServiceNow posted a quarterly revenue of $3.77 billion, up 22% from a year earlier, and generated free cash flow of...
Commerzbank finds itself navigating a rare confluence of events over the next five days, with the European Central Bank’s interest-rate...
A recent decision by the Nuremberg Labor Court has reinforced the legal protections enjoyed by worker representatives, ruling that an...
The Nasdaq 100 staged a sharp reversal on Monday, clawing back nearly 3% after a brutal selloff wiped almost 5%...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.
© 2023 StocksToday.com